Local IL-2 Injection
Virus-Induced Tumors
Key Facts
About Immunservice
Immunservice is a specialized biotech firm built around the therapeutic potential of interleukin-2 (IL-2). Founded as a spin-off from the University of Hamburg, it has a dual business model: supplying high-quality, ready-to-use IL-2 cell culture media and related services to the research community, while concurrently developing a proprietary pipeline of localized IL-2 immunotherapies for human and veterinary use. The company is led by founder and IL-2 pioneer Edith Huland and is backed by seed investor High-Tech Gründerfonds, positioning it as a niche player bridging research tools and clinical development in immunotherapy.
View full company profileAbout Immunservice
Immunservice is a specialized biotech firm built around the therapeutic potential of interleukin-2 (IL-2). Founded as a spin-off from the University of Hamburg, it has a dual business model: supplying high-quality, ready-to-use IL-2 cell culture media and related services to the research community, while concurrently developing a proprietary pipeline of localized IL-2 immunotherapies for human and veterinary use. The company is led by founder and IL-2 pioneer Edith Huland and is backed by seed investor High-Tech Gründerfonds, positioning it as a niche player bridging research tools and clinical development in immunotherapy.
View full company profile